WO2019147979A3 - Peptides for angiogenic therapy - Google Patents

Peptides for angiogenic therapy Download PDF

Info

Publication number
WO2019147979A3
WO2019147979A3 PCT/US2019/015210 US2019015210W WO2019147979A3 WO 2019147979 A3 WO2019147979 A3 WO 2019147979A3 US 2019015210 W US2019015210 W US 2019015210W WO 2019147979 A3 WO2019147979 A3 WO 2019147979A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
angiogenic therapy
cancer
disorders
treatment
Prior art date
Application number
PCT/US2019/015210
Other languages
French (fr)
Other versions
WO2019147979A2 (en
Inventor
Mira SASTRI
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Priority to US16/465,808 priority Critical patent/US10934334B2/en
Publication of WO2019147979A2 publication Critical patent/WO2019147979A2/en
Publication of WO2019147979A3 publication Critical patent/WO2019147979A3/en
Priority to US17/157,617 priority patent/US11608367B2/en
Priority to US18/105,658 priority patent/US20230227519A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Provided herein are compositions including peptide or nucleic acids encoding peptides and related methods for the treatment of angiogenic conditions such as cancer, vascular disorders such as cardiovascular disorders, and infectious disease.
PCT/US2019/015210 2018-01-25 2019-01-25 Peptides for angiogenic therapy WO2019147979A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US16/465,808 US10934334B2 (en) 2018-01-25 2019-01-25 Peptides for angiogenic therapy
US17/157,617 US11608367B2 (en) 2018-01-25 2021-01-25 Peptides for angiogenic therapy
US18/105,658 US20230227519A1 (en) 2018-01-25 2023-02-03 Peptides for angiogenic therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862622012P 2018-01-25 2018-01-25
US62/622,012 2018-01-25

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/465,808 A-371-Of-International US10934334B2 (en) 2018-01-25 2019-01-25 Peptides for angiogenic therapy
US17/157,617 Division US11608367B2 (en) 2018-01-25 2021-01-25 Peptides for angiogenic therapy

Publications (2)

Publication Number Publication Date
WO2019147979A2 WO2019147979A2 (en) 2019-08-01
WO2019147979A3 true WO2019147979A3 (en) 2019-08-22

Family

ID=67396216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/015210 WO2019147979A2 (en) 2018-01-25 2019-01-25 Peptides for angiogenic therapy

Country Status (2)

Country Link
US (3) US10934334B2 (en)
WO (1) WO2019147979A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934334B2 (en) 2018-01-25 2021-03-02 The Regents Of The University Of California Peptides for angiogenic therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020019040A1 (en) * 2000-03-27 2002-02-14 Noteborn Mathieu Hubertus M. Apoptin-associating protein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715645B2 (en) 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
AU2003256307A1 (en) * 2002-06-25 2004-01-06 The Regents Of The University Of California Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival
CA2665365A1 (en) * 2006-10-05 2008-04-10 Rhode Island Hospital Compositions and methods for detecting and treating renal injury and inflammation
JP2012525146A (en) * 2009-04-28 2012-10-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ Overcharged protein for cell penetration
US10934334B2 (en) 2018-01-25 2021-03-02 The Regents Of The University Of California Peptides for angiogenic therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020019040A1 (en) * 2000-03-27 2002-02-14 Noteborn Mathieu Hubertus M. Apoptin-associating protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHADA ET AL.: "Apoptin studies illuminate intersection between lipidomics and tumor suppressors", MOL THER, vol. 15, no. 1, January 2007 (2007-01-01), pages 7 - 9, XP055633301 *

Also Published As

Publication number Publication date
US20190389922A1 (en) 2019-12-26
US10934334B2 (en) 2021-03-02
US11608367B2 (en) 2023-03-21
US20230227519A1 (en) 2023-07-20
US20210147501A1 (en) 2021-05-20
WO2019147979A2 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
WO2018190719A3 (en) Anti-sirp alpha antibodies
WO2018033254A3 (en) Rna for cancer therapy
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
WO2019028306A3 (en) Compositions and methods for delivery of aav
WO2018089508A3 (en) Anti-cd47 antibodies
MX2022005291A (en) Vaccines for treatment and prevention of cancer.
WO2017106346A3 (en) Human immunodeficiency virus neutralizing antibodies
EP4218785A3 (en) Mitochondria-targeting peptides
WO2016191643A3 (en) Tigit-binding agents and uses thereof
WO2017030823A3 (en) Anti-tigit antibodies
EP4306538A3 (en) Peptide oligonucleotide conjugates
WO2017218949A3 (en) Peptidomimetic macrocycles and uses thereof
WO2017214170A3 (en) Baff-r antibodies and uses thereof
WO2017049038A3 (en) Anti-cd115 antibodies
WO2018187331A8 (en) Macrocyclic compound and uses thereof
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
WO2020008377A3 (en) Ionic self-assembling peptides
WO2018226992A8 (en) Tau aggregation inhibitors
WO2019209965A3 (en) Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
WO2016020880A3 (en) Angiopoietin-like 4 antibodies and methods of use
MX2020009522A (en) Anti-folate receptor 1 antibodies and uses thereof.
WO2016172269A3 (en) Insulin analogs having shortened b chain peptides and associated methods
WO2020022898A3 (en) Off-the-shelf cancer vaccines
WO2017218569A3 (en) Alpha(v)beta(6) integrin-binding peptides and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19744019

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19744019

Country of ref document: EP

Kind code of ref document: A2